Atorvastatin administration is associated with dose-related changes in IGF bioavailability.
Narayanan RP, Gittins M, Siddals KW, Oliver RL, Hudson JE, White A, Durrington P, Davies RR, Rutter MK, Gibson JM.
Narayanan RP, et al. Among authors: siddals kw.
Eur J Endocrinol. 2013 Mar 15;168(4):543-8. doi: 10.1530/EJE-12-0844. Print 2013 Apr.
Eur J Endocrinol. 2013.
PMID: 23333902
Clinical Trial.